113 related articles for article (PubMed ID: 3818388)
1. Solid tumor models for the assessment of different treatment modalities: XXVI. Estimates of cell survival from tumor growth delay after alternating radiotherapy and chemotherapy.
Hopkins HA; Looney WB
Int J Radiat Oncol Biol Phys; 1987 Feb; 13(2):217-24. PubMed ID: 3818388
[TBL] [Abstract][Full Text] [Related]
2. Solid tumor models for the assessment of different treatment modalities: XXIII. A new approach to the more effective utilization of radiotherapy alternated with chemotherapy.
Looney WB; Hopkins HA; Carter WH
Int J Radiat Oncol Biol Phys; 1985 Dec; 11(12):2105-17. PubMed ID: 4066443
[TBL] [Abstract][Full Text] [Related]
3. Solid tumor models for the assessment of different treatment modalities: XXV. Comparison of the effect of one radiation fraction per day with multiple fractions per day (MFD) given either continuously or intermittently on tumor response and normal tissue reaction.
Looney WB; Hopkins HA
Int J Radiat Oncol Biol Phys; 1986 Feb; 12(2):203-10. PubMed ID: 3949571
[TBL] [Abstract][Full Text] [Related]
4. Relationship of tumor regrowth to tumor cell survival, tumor cure rates and host survival in a solid tumor model following combined chemotherapy and radiotherapy.
Hopkins HA; Looney WB; Carter WH; Reto DC; Campbell ED
In Vivo; 1994; 8(1):97-105. PubMed ID: 8054518
[TBL] [Abstract][Full Text] [Related]
5. Solid tumor models for the assessment of different treatment modalities. XXI. Comparison of different radiation dose schedules alone or in combination with cyclophosphamide.
Looney WB; Longerbeam MB; Hopkins HA; Carter WH
Cancer; 1983 Mar; 51(6):1012-20. PubMed ID: 6821865
[TBL] [Abstract][Full Text] [Related]
6. Multiple drug chemotherapy combined with multiple fractions per day (MFD) radiotherapy in an experimental solid tumor model.
Hopkins HA; Looney WB; Carter WH; Reto DC; Campbell ED
In Vivo; 1994; 8(1):107-12. PubMed ID: 8054501
[TBL] [Abstract][Full Text] [Related]
7. Solid tumor models for the assessment of different treatment modalities. XIII. Comparison of response and recovery of host and solid tumor to cyclophosphamide and radiation.
Looney WB; Hopkins HA; Grover WH; Macleod MS; Ritenour ER; Hobson AS
Cancer; 1980 Jun; 45(11):2793-804. PubMed ID: 7379010
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of daily versus hyperfractionated split-course radiation schedules with and without cyclophosphamide on median survival, metastatic dissemination, tumor cure, and growth rates.
Looney WB; Hopkins HA; Longerbeam MB; Carter WH
Cancer Res; 1983 Jan; 43(1):60-7. PubMed ID: 6847784
[TBL] [Abstract][Full Text] [Related]
9. Solid tumor models for the assessment of different treatment modalities. XXII. The alternate utilization of radiotherapy and chemotherapy.
Looney WB; Hopkins HA; Carter WH
Cancer; 1984 Aug; 54(3):416-25. PubMed ID: 6733674
[TBL] [Abstract][Full Text] [Related]
10. Solid tumor models for the assessment of different treatment modalities: XVI. Sequential combined modality (Cyclophosphamide-Radiation) therapy.
Looney WB; Ritenour ER; Hopkins HA
Cancer; 1981 Mar; 47(5):860-9. PubMed ID: 7226039
[TBL] [Abstract][Full Text] [Related]
11. Administration of radiation or cyclophosphamide versus alternated radiation and cyclophosphamide treatment of primary tumor and pulmonary metastases.
Looney WB; Hopkins HA
NCI Monogr; 1988; (6):145-6. PubMed ID: 3352757
[TBL] [Abstract][Full Text] [Related]
12. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
Ning S; Trisler K; Wessels BW; Knox SJ
Cancer; 1997 Dec; 80(12 Suppl):2519-28. PubMed ID: 9406705
[TBL] [Abstract][Full Text] [Related]
13. Experimental thermoradiotherapy in malignant hepatocellular carcinoma.
Hehr T; Budach W; Lamprecht U; Belka C; Classen J; Trübenbach J; Wehrmann M; Dietz K; Bamberg M
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1374-80. PubMed ID: 12654450
[TBL] [Abstract][Full Text] [Related]
14. Solid tumor models for the assessment of different treatment modalities. XIX. Tumor cure rates and tumor control following sequential administration of radiation and cyclophosphamide.
Looney WB; Ritenour ER; Hopkins HA
Am J Clin Oncol; 1982 Apr; 5(2):209-20. PubMed ID: 7091043
[TBL] [Abstract][Full Text] [Related]
15. Recombinant murine GM-CSF increases resistance of some factor dependent hematopoietic progenitor cells to low-dose-rate gamma irradiation.
FitzGerald TJ; Henault S; Santucci MA; Anklesaria P; Zak S; Kase K; Farber N; Pierce JH; Ohara A; Greenberger JS
Int J Radiat Oncol Biol Phys; 1989 Aug; 17(2):323-35. PubMed ID: 2666365
[TBL] [Abstract][Full Text] [Related]
16. Radiobiological aspects of low dose rates in radioimmunotherapy.
Fowler JF
Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1261-9. PubMed ID: 2347734
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy and concomitant chemoradiotherapy in the NB rat prostate adenocarcinoma model.
Klump R; Pieters RS; Smith JJ; Badalament RA; Drago JR
In Vivo; 1989; 3(2):109-11. PubMed ID: 2519835
[TBL] [Abstract][Full Text] [Related]
18. Expression of transfected recombinant oncogenes increases radiation resistance of clonal hematopoietic and fibroblast cell lines selectively at clinical low dose rate.
FitzGerald TJ; Henault S; Sakakeeny M; Santucci MA; Pierce JH; Anklesaria P; Kase K; Das I; Greenberger JS
Radiat Res; 1990 Apr; 122(1):44-52. PubMed ID: 2320725
[TBL] [Abstract][Full Text] [Related]
19. The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines.
Vokes EE; Beckett M; Karrison T; Weichselbaum RR
Oncology; 1992; 49(6):454-60. PubMed ID: 1465284
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide as an adjuvant to X-rays in treatment of a radioresistant solid tumor of the rat, hepatoma H-4-II-E.
Moore JV; Rowley R; Hopkins HA; Ritenour ER; Looney WB
Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1471-4. PubMed ID: 536257
[No Abstract] [Full Text] [Related]
[Next] [New Search]
